Cargando…
Treating Pulmonary Fibrosis with Non-Viral Gene Therapy: From Bench to Bedside
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by irreversible lung scarring, which achieves almost 80% five-year mortality rate. Undeniably, commercially available pharmaceuticals, such as pirfenidone and nintedanib, exhibit certain effects on improving the...
Autores principales: | Huang, Teng, Gao, Jia, Cai, Long, Xie, Hao, Wang, Yuhan, Wang, Yi, Zhou, Qing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027953/ https://www.ncbi.nlm.nih.gov/pubmed/35456646 http://dx.doi.org/10.3390/pharmaceutics14040813 |
Ejemplares similares
-
Takotsubo Syndrome: From Bench to Bedside and Bedside to Bench
por: Pelliccia, Francesco, et al.
Publicado: (2022) -
Bench and Bedside
por: Schmidt, Christian
Publicado: (2002) -
Highlights of Keystone symposium ‘Fibrosis: from bench to bedside’
por: de Haan, Judith Jeanette, et al.
Publicado: (2014) -
Myocardial fibrosis: biomedical research from bench to bedside
por: Gyöngyösi, Mariann, et al.
Publicado: (2017) -
Heritable pulmonary hypertension: from bench to bedside
por: Girerd, Barbara, et al.
Publicado: (2017)